Phathom Pharmaceuticals, Inc. PHAT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $204.89M+17.0% | $175.11M+19.0% | $147.19M+29.1% | $114.04M+39.3% | $81.86M+48.2% | ||
| $30.87M+36.6% | $22.6M+20.4% | $18.77M+25.7% | $14.93M+32.5% | $11.27M+41.4% | ||
| $174.02M+14.1% | $152.51M+18.8% | $128.42M+29.6% | $99.11M+40.4% | $70.59M+49.3% | ||
| 84.9%-2.2pp | 87.1%-0.2pp | 87.2%+0.3pp | 86.9%+0.7pp | 86.2%+0.7pp | ||
| $31.37M-4.3% | $32.78M-3.2% | $33.87M-4.7% | $35.54M+5.0% | $33.84M-0.7% | ||
| $239.25M-14.5% | $279.72M-9.2% | $308.03M-7.4% | $332.57M+2.9% | $323.13M+11.2% | ||
| $270.62M-13.4% | $312.5M-8.6% | $341.9M-7.1% | $368.11M+3.1% | $356.96M+9.9% | ||
| $270.62M-13.4% | $312.5M-8.6% | $341.9M-7.1% | $368.11M+3.1% | $356.96M+9.9% | ||
| -$96.6M+39.6% | -$159.99M+25.1% | -$213.48M+20.6% | -$269M+6.1% | -$286.38M-3.2% | ||
| -47.1%+44.2pp | -91.4%+53.7pp | -145%+90.9pp | -235.9%+114pp | -349.8%+152pp | ||
| $65.84M-3.3% | $68.12M-3.1% | $70.29M-3.3% | $72.67M-0.3% | $72.91M+1.3% | ||
| $6.14M-12.8% | $7.04M-24.7% | $9.35M-19.7% | $11.65M-13.6% | $13.49M-11.0% | ||
| -$60.7M+0.9% | -$61.26M-0.3% | -$61.08M+0.1% | -$61.15M-2.9% | -$59.41M-4.5% | ||
| -$157.3M+28.9% | -$221.25M+19.4% | -$274.55M+16.8% | -$330.15M+4.5% | -$345.79M-3.4% | ||
| -76.8%+49.6pp | -126.3%+60.2pp | -186.5%+103pp | -289.5%+133pp | -422.4%+183pp | ||
| -$2.10+30.9% | -$3.04+19.4% | -$3.77+19.4% | -$4.68+9.8% | -$5.19+2.1% | ||
| -$2.10+30.9% | -$3.04+19.4% | -$3.77+19.4% | -$4.68+9.8% | -$5.19+2.1% | ||
| 300.8M+3.5% | 290.8M+3.5% | 281M+3.2% | 272.2M+5.4% | 258.3M+5.6% | ||
| 300.8M+3.5% | 290.8M+3.5% | 281M+3.2% | 272.2M+5.4% | 258.3M+5.6% | ||
| -$998K-428% | -$189K— | —— | —— | —— | ||
| -$96.6M+39.6% | -$159.99M+25.1% | -$213.48M+20.6% | -$269M+6.1% | -$286.38M-3.2% | ||
| -$96.03M+39.7% | -$159.35M+25.1% | -$212.78M+20.7% | -$268.27M+6.1% | -$285.62M-3.2% | ||
| -$96.03M+39.7% | -$159.35M+25.1% | -$212.78M+20.7% | -$268.27M+6.1% | -$285.62M-3.2% | ||
| -46.9%+44.1pp | -91%+53.6pp | -144.6%+90.7pp | -235.2%+114pp | -348.9%+152pp | ||
| -$96.6M+39.6% | -$159.99M+25.1% | -$213.48M+20.6% | -$269M+6.1% | -$286.38M-3.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) generated $204.9M in revenue over the trailing twelve months, up 150.3% year over year.
- Is Phathom Pharmaceuticals, Inc. profitable?
- Phathom Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months, a -76.8% net margin.
- What are Phathom Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 84.9% and operating margin is -47.1%, with a -76.8% net margin.
- What is Phathom Pharmaceuticals, Inc.'s earnings per share?
- Phathom Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.10.
- Where does Phathom Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
